Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists
NCT05338632Phase 1Terminated
- Sponsor
- Leiden University Medical Center
- Start
- Jun 2022
- Primary completion
- Mar 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of naloxone and nalmefene in opioid-induced respiratory depression (OIRD) (4 arms), sponsored by Leiden University Medical Center. Primary endpoints: Minute ventilation up to 180 minutes, Plasma concentration of sufentanil and fentanyl at 30 minutes and 1 more. Started Jun 2022; status: terminated.
02
Drugs
naloxonenalmefene
03
Conditions
opioid-induced respiratory depression (OIRD)
Beyond the preview
Go deeper on NCT05338632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05338632.